Strategic Help With Immunoglobulin to Enhance Protect Against Late Disease (CMV) — Stella

Clinical trial discovery in plain English. Data sourced from ClinicalTrials.gov.

ClinicalTrials.gov ↗

Stella is not a medical provider and does not give medical advice. AI-generated summaries are for informational purposes only. Always consult your doctor before making any healthcare decisions.

Strategic Help With Immunoglobulin to Enhance Protect Against Late Disease (CMV) — Stella

Recruiting

Back to Cytomegalovirus trials

Phase 4 — Post-approval study. The treatment has been approved, but researchers continue monitoring it in a large population over time.

Trial locations(2 sites)

United States

Massachusetts General Hospital, Boston, Massachusetts

University of Texas Southwestern, Dallas, Texas

Key details

Phase

Post-approval study

Sponsor

Camille N. Kotton, MD

Collaborators

University of Texas Southwestern Medical Center, Kamada, Ltd.

Enrollment target

~80 participants

Started

November 2025

Primary completion

December 2027

Age range

18 Years – 75 Years

Last updated December 2025

Interested in joining?

Tell us you're interested and we'll help connect you with the research team. We'll never share your email without your permission.

Your name

Email address

Follow this trial

Get notified in plain English when this trial's status changes. No account required.

View full record on ClinicalTrials.gov